Camrelizumab (INN; development code SHR-1210) is an anti-PD-1 immune checkpoint inhibitor that is being investigated for the treatment of hepatocellular carcinoma, Hodgkin lymphoma, and the squamous cell form of esophageal carcinoma.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.